[{"id":"5ca3f586-5d57-495c-9088-bac9d19c4782","acronym":"","url":"https://clinicaltrials.gov/study/NCT04826341","created_at":"2021-04-01T16:52:34.686Z","updated_at":"2025-02-25T13:40:26.267Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors","source_id_and_acronym":"NCT04826341","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • HRD • CDK12 • BRCA • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A","pipe":" | ","alterations":" ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • RAD54L mutation","tags":["BRCA1 • BRCA2 • HRD • CDK12 • BRCA • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • RAD54L mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e berzosertib (M6620) • Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 09/20/2021","start_date":" 09/20/2021","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2025-02-21"},{"id":"907c18db-1f38-4071-a1e3-b3af86377f13","acronym":"","url":"https://clinicaltrials.gov/study/NCT05941520","created_at":"2023-07-12T16:10:13.477Z","updated_at":"2025-02-25T13:49:53.635Z","phase":"Phase 2","brief_title":"Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer","source_id_and_acronym":"NCT05941520","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • PTEN • ATM • NF1 • MSH6 • CDH1 • CHEK2 • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • AGR2","pipe":" | ","alterations":" TP53 mutation • ATM mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation","tags":["TP53 • PTEN • ATM • NF1 • MSH6 • CDH1 • CHEK2 • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • AGR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • ATM mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • acolbifene"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 08/23/2024","start_date":" 08/23/2024","primary_txt":" Primary completion: 08/23/2027","primary_completion_date":" 08/23/2027","study_txt":" Completion: 09/01/2028","study_completion_date":" 09/01/2028","last_update_posted":"2025-02-21"},{"id":"e17de7f3-6ed2-44ac-8c1d-acf78b25a29e","acronym":"NCI-2017-02296","url":"https://clinicaltrials.gov/study/NCT03375307","created_at":"2021-01-18T16:39:30.359Z","updated_at":"2025-02-25T13:39:36.028Z","phase":"Phase 2","brief_title":"Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes","source_id_and_acronym":"NCT03375307 - NCI-2017-02296","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • TMB • ABL1 • MSI • STK11 • NPM1 • POLE • CCND1 • MLH1 • MSH6 • MSH2 • ATRX • CHEK2 • SMARCB1 • RAD51 • POLD1 • CHEK1 • BARD1 • FANCL • BRD4 • DOT1L • FANCE • FANCG • IKBKE • FANCC","pipe":" | ","alterations":" FANCG mutation","tags":["TP53 • TMB • ABL1 • MSI • STK11 • NPM1 • POLE • CCND1 • MLH1 • MSH6 • MSH2 • ATRX • CHEK2 • SMARCB1 • RAD51 • POLD1 • CHEK1 • BARD1 • FANCL • BRD4 • DOT1L • FANCE • FANCG • IKBKE • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FANCG mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 11/03/2020","start_date":" 11/03/2020","primary_txt":" Primary completion: 12/16/2025","primary_completion_date":" 12/16/2025","study_txt":" Completion: 12/16/2025","study_completion_date":" 12/16/2025","last_update_posted":"2025-02-21"},{"id":"78af9b6a-0b92-4e92-b86c-385f5f7643c9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04266912","created_at":"2021-01-18T20:43:57.460Z","updated_at":"2025-02-25T14:15:34.609Z","phase":"Phase 1/2","brief_title":"Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors","source_id_and_acronym":"NCT04266912","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRCA1 • BRCA2 • ATM • ARID1A • BAP1 • MSH2 • CDK12 • ATRX • CHEK2 • SMARCB1 • RAD51 • FANCA • BRIP1 • RAD51C • CD4 • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2 • ATM • ARID1A • BAP1 • MSH2 • CDK12 • ATRX • CHEK2 • SMARCB1 • RAD51 • FANCA • BRIP1 • RAD51C • CD4 • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • berzosertib (M6620)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 03/17/2020","start_date":" 03/17/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-18"},{"id":"ab61b8a8-7577-42c8-aace-25d2ec073ed7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05700721","created_at":"2023-01-26T15:02:55.768Z","updated_at":"2025-02-25T14:09:25.231Z","phase":"Phase 2","brief_title":"Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)","source_id_and_acronym":"NCT05700721","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1 • HRD • CDK12 • CHEK2 • RAD51 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • RAD54L • FANCL • RAD52","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • HRD • CDK12 • CHEK2 • RAD51 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • RAD54L • FANCL • RAD52"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • Jemperli (dostarlimab-gxly)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 06/02/2023","start_date":" 06/02/2023","primary_txt":" Primary completion: 08/07/2025","primary_completion_date":" 08/07/2025","study_txt":" Completion: 08/07/2027","study_completion_date":" 08/07/2027","last_update_posted":"2025-02-17"},{"id":"60bce1a2-b876-426c-a77f-15b4b5b443a9","acronym":"","url":"https://clinicaltrials.gov/study/NCT03805919","created_at":"2021-01-18T18:48:39.011Z","updated_at":"2025-02-25T15:34:18.012Z","phase":"","brief_title":"Men at High Genetic Risk for Prostate Cancer","source_id_and_acronym":"NCT03805919","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • BRCA1 • BRCA2 • MLH1 • MSH6 • MSH2 • CHEK2 • FANCA • BRIP1 • RAD51C • RAD51D • EPCAM • NBN • FANCF • FANCL • FANCI • FANCM • FANCD2 • FANCE • FANCG • FANCB • FANCC • HOXB13","pipe":"","alterations":" ","tags":["TP53 • BRCA1 • BRCA2 • MLH1 • MSH6 • MSH2 • CHEK2 • FANCA • BRIP1 • RAD51C • RAD51D • EPCAM • NBN • FANCF • FANCL • FANCI • FANCM • FANCD2 • FANCE • FANCG • FANCB • FANCC • HOXB13"],"overall_status":"Recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 03/27/2019","start_date":" 03/27/2019","primary_txt":" Primary completion: 01/01/2029","primary_completion_date":" 01/01/2029","study_txt":" Completion: 01/01/2039","study_completion_date":" 01/01/2039","last_update_posted":"2025-02-10"},{"id":"6365efdc-854e-4454-ba10-f28f09a5a11b","acronym":"PEPN2112","url":"https://clinicaltrials.gov/study/NCT05071209","created_at":"2021-10-08T11:53:44.641Z","updated_at":"2025-02-25T17:01:24.348Z","phase":"Phase 1/2","brief_title":"Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors","source_id_and_acronym":"NCT05071209 - PEPN2112","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • ATM • MSH2 • CDK12 • WT1 • ATRX • CHEK2 • RAD51 • FANCA • POLD1 • FOXO1 • XRCC2 • ATF1 • PAX3","pipe":" | ","alterations":" PAX3-FOXO1 fusion","tags":["BRCA1 • BRCA2 • ATM • MSH2 • CDK12 • WT1 • ATRX • CHEK2 • RAD51 • FANCA • POLD1 • FOXO1 • XRCC2 • ATF1 • PAX3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PAX3-FOXO1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e elimusertib (BAY 1895344)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 12/22/2021","start_date":" 12/22/2021","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 11/22/2025","study_completion_date":" 11/22/2025","last_update_posted":"2025-02-03"},{"id":"f228ffce-69d8-4696-a61e-6222a211f51d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05188508","created_at":"2022-01-12T14:53:32.609Z","updated_at":"2025-02-25T16:17:09.399Z","phase":"Phase 2","brief_title":"Pembrolizumab, Olaparib, and Temozolomide for People with Glioma","source_id_and_acronym":"NCT05188508","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" EGFR • BRCA1 • BRCA2 • HRD • CDKN2A • FGFR • CDK12 • CDKN2B • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A","pipe":" | ","alterations":" CDKN2A deletion • BRIP1 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • IDH wild-type","tags":["EGFR • BRCA1 • BRCA2 • HRD • CDKN2A • FGFR • CDK12 • CDKN2B • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A deletion • BRIP1 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lynparza (olaparib) • temozolomide"],"overall_status":"Recruiting","enrollment":" Enrollment 57","initiation":"Initiation: 01/14/2022","start_date":" 01/14/2022","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-02-03"},{"id":"85a83785-b733-4534-88fe-4b08d1977f8f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04126070","created_at":"2021-01-18T20:09:27.547Z","updated_at":"2025-02-25T14:28:48.143Z","phase":"Phase 2","brief_title":"Nivolumab + Docetaxel + ADT in MHSPC Patients with DDRD or Inflamed Tumors","source_id_and_acronym":"NCT04126070","lead_sponsor":"Xiao X. Wei, MD","biomarkers":" PD-L1 • BRCA1 • MSI • CD8 • MLH1 • MSH6 • MSH2 • CDK12 • CHEK2 • BRIP1 • RAD51C • RAD51D • NBN • ABRAXAS1 • GEN1","pipe":" | ","alterations":" PD-L1 expression • MSI-H/dMMR","tags":["PD-L1 • BRCA1 • MSI • CD8 • MLH1 • MSH6 • MSH2 • CDK12 • CHEK2 • BRIP1 • RAD51C • RAD51D • NBN • ABRAXAS1 • GEN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • docetaxel • goserelin acetate • Firmagon (degarelix) • leuprolide acetate for depot suspension"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 05/11/2020","start_date":" 05/11/2020","primary_txt":" Primary completion: 10/24/2024","primary_completion_date":" 10/24/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-01-29"},{"id":"73183b76-400c-42da-8908-2c1fc21637ec","acronym":"OPTIMUM","url":"https://clinicaltrials.gov/study/NCT05222971","created_at":"2022-02-05T18:29:24.003Z","updated_at":"2025-02-25T17:37:35.916Z","phase":"Phase 2","brief_title":"Olaparib with or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy","source_id_and_acronym":"NCT05222971 - OPTIMUM","lead_sponsor":"Asan Medical Center","biomarkers":" BRCA1 • BRCA2 • ATM • POLE • BAP1 • MLH1 • MSH6 • MSH2 • BRCA • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • XRCC2 • FANCD2 • GEN1","pipe":" | ","alterations":" ATM mutation • CHEK2 mutation • BRIP1 mutation • BARD1 mutation","tags":["BRCA1 • BRCA2 • ATM • POLE • BAP1 • MLH1 • MSH6 • MSH2 • BRCA • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • XRCC2 • FANCD2 • GEN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • CHEK2 mutation • BRIP1 mutation • BARD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 04/01/2022","start_date":" 04/01/2022","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2026","study_completion_date":" 12/30/2026","last_update_posted":"2025-01-28"},{"id":"d934aafe-bd3e-4728-955c-fb7a4b80ce12","acronym":"HRPCa-II","url":"https://clinicaltrials.gov/study/NCT05333432","created_at":"2022-04-19T23:53:47.960Z","updated_at":"2025-02-25T17:37:45.989Z","phase":"","brief_title":"Evaluation of a Multimodal Strategy for Early Diagnosis of Men At High Genetic Risk of Prostate Cancer","source_id_and_acronym":"NCT05333432 - HRPCa-II","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" TP53 • BRCA1 • BRCA2 • PTEN • STK11 • MLH1 • MSH6 • MSH2 • CDH1 • CHEK2 • BRIP1 • RAD51C • RAD50 • RAD51D • BARD1 • NBN • HOXB13","pipe":" | ","alterations":" PALB2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation","tags":["TP53 • BRCA1 • BRCA2 • PTEN • STK11 • MLH1 • MSH6 • MSH2 • CDH1 • CHEK2 • BRIP1 • RAD51C • RAD50 • RAD51D • BARD1 • NBN • HOXB13"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PALB2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 880","initiation":"Initiation: 03/01/2025","start_date":" 03/01/2025","primary_txt":" Primary completion: 03/01/2030","primary_completion_date":" 03/01/2030","study_txt":" Completion: 03/01/2030","study_completion_date":" 03/01/2030","last_update_posted":"2025-01-28"},{"id":"dfa37710-8128-4c60-aefe-7507a106a2e0","acronym":"MK3475-A53","url":"https://clinicaltrials.gov/study/NCT05379972","created_at":"2022-05-18T11:57:02.291Z","updated_at":"2025-02-25T16:17:42.708Z","phase":"Phase 2","brief_title":"Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers","source_id_and_acronym":"NCT05379972 - MK3475-A53","lead_sponsor":"University of Colorado, Denver","biomarkers":" HER-2 • BRCA1 • BRCA2 • PTEN • HRD • BAP1 • KMT2D • ATRX • CHEK2 • FANCA • BRIP1 • RAD50 • MLL2 • CHEK1 • BARD1 • NBN • WRN • FANCG • ABRAXAS1 • SLX4","pipe":" | ","alterations":" HRD","tags":["HER-2 • BRCA1 • BRCA2 • PTEN • HRD • BAP1 • KMT2D • ATRX • CHEK2 • FANCA • BRIP1 • RAD50 • MLL2 • CHEK1 • BARD1 • NBN • WRN • FANCG • ABRAXAS1 • SLX4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lynparza (olaparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 01/12/2023","start_date":" 01/12/2023","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2024-11-26"},{"id":"0274e43f-cc0c-414e-9481-44dc1368c6ca","acronym":"","url":"https://clinicaltrials.gov/study/NCT05515575","created_at":"2022-09-08T14:56:05.365Z","updated_at":"2025-02-25T13:13:08.083Z","phase":"Phase 2","brief_title":"A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA","source_id_and_acronym":"NCT05515575","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" BRCA1 • BRCA2 • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • PARP1 • CHEK1 • BARD1 • NBN • FANCF • FANCL • XRCC2 • ERCC4 • FANCI • FANCM • RAD52 • FANCD2 • FANCE • FANCG • RAD23B • RECQL4 • RPA1 • ABRAXAS1 • FANCC • RAD54B • SLX4","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2 • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • PARP1 • CHEK1 • BARD1 • NBN • FANCF • FANCL • XRCC2 • ERCC4 • FANCI • FANCM • RAD52 • FANCD2 • FANCE • FANCG • RAD23B • RECQL4 • RPA1 • ABRAXAS1 • FANCC • RAD54B • SLX4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 08/23/2022","start_date":" 08/23/2022","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-11-05"},{"id":"36a397ed-0e68-47a2-95c4-59ca2210321e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03601923","created_at":"2021-01-18T17:42:32.758Z","updated_at":"2025-02-25T13:18:35.093Z","phase":"Phase 2","brief_title":"Niraparib in Patients With Pancreatic Cancer","source_id_and_acronym":"NCT03601923","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" BRCA1 • BRCA2 • ATM • CHEK2","pipe":" | ","alterations":" ATM mutation • PALB2 mutation • CHEK2 mutation","tags":["BRCA1 • BRCA2 • ATM • CHEK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • PALB2 mutation • CHEK2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 08/22/2018","start_date":" 08/22/2018","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 02/28/2026","study_completion_date":" 02/28/2026","last_update_posted":"2024-10-22"},{"id":"5b18e518-5abe-49ce-9ea4-7ddcd3927bd8","acronym":"SPORE","url":"https://clinicaltrials.gov/study/NCT04666740","created_at":"2021-01-19T20:43:48.854Z","updated_at":"2025-02-25T16:10:54.810Z","phase":"Phase 2","brief_title":"A Study of Pembrolizumab and Olaparib for People with Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy","source_id_and_acronym":"NCT04666740 - SPORE","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" BRCA1 • BRCA2 • ATM • BAP1 • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD50 • BARD1 • NBN • ABRAXAS1 • FANCC","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2 • ATM • BAP1 • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD50 • BARD1 • NBN • ABRAXAS1 • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lynparza (olaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 12/18/2020","start_date":" 12/18/2020","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-10-14"},{"id":"c4941059-797c-48e5-8562-88baff159bbc","acronym":"TBCRC 048","url":"https://clinicaltrials.gov/study/NCT03344965","created_at":"2021-01-17T17:24:38.311Z","updated_at":"2025-02-25T14:58:31.297Z","phase":"Phase 2","brief_title":"Olaparib in Metastatic Breast Cancer","source_id_and_acronym":"NCT03344965 - TBCRC 048","lead_sponsor":"Beth Israel Deaconess Medical Center","biomarkers":" PGR • BRCA1 • BRCA2 • BRCA • CHEK2 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC","pipe":" | ","alterations":" HR positive • PALB2 mutation • PGR positive • BRCA mutation","tags":["PGR • BRCA1 • BRCA2 • BRCA • CHEK2 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • PALB2 mutation • PGR positive • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 114","initiation":"Initiation: 04/01/2018","start_date":" 04/01/2018","primary_txt":" Primary completion: 07/30/2025","primary_completion_date":" 07/30/2025","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2024-10-11"},{"id":"75a29f57-27bd-4671-83cb-33821417c3f6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03047135","created_at":"2021-01-18T15:00:24.273Z","updated_at":"2025-02-25T14:57:49.956Z","phase":"Phase 2","brief_title":"Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis","source_id_and_acronym":"NCT03047135","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" BRCA1 • BRCA2 • ATM • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • FANCL • PPP2R2A","pipe":" | ","alterations":" BRCA1 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • CHEK1 expression","tags":["BRCA1 • BRCA2 • ATM • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • FANCL • PPP2R2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA1 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • CHEK1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 03/01/2017","start_date":" 03/01/2017","primary_txt":" Primary completion: 05/24/2023","primary_completion_date":" 05/24/2023","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-07-03"},{"id":"1c16003b-285a-46dd-9a81-5650057a4b2f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04336943","created_at":"2021-01-18T20:59:44.586Z","updated_at":"2025-02-25T14:59:00.006Z","phase":"Phase 2","brief_title":"Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load","source_id_and_acronym":"NCT04336943","lead_sponsor":"University of Washington","biomarkers":" BRCA2 • HRD • CDK12 • CHEK2 • BRIP1 • RAD51C • CD4 • RAD51D • NBN • ABRAXAS1 • GEN1","pipe":" | ","alterations":" MSI-H/dMMR • HRD","tags":["BRCA2 • HRD • CDK12 • CHEK2 • BRIP1 • RAD51C • CD4 • RAD51D • NBN • ABRAXAS1 • GEN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 04/13/2021","start_date":" 04/13/2021","primary_txt":" Primary completion: 06/20/2024","primary_completion_date":" 06/20/2024","study_txt":" Completion: 06/06/2025","study_completion_date":" 06/06/2025","last_update_posted":"2024-07-02"},{"id":"d7a0703a-8b1b-461b-a082-3de4e2b533f7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03061188","created_at":"2021-01-17T18:03:06.477Z","updated_at":"2025-02-25T14:37:19.874Z","phase":"Phase 1","brief_title":"Phase I/Ib Study of Nivolumab \u0026 Veliparib in Patients With Advanced Solid Tumors \u0026 Lymphoma","source_id_and_acronym":"NCT03061188","lead_sponsor":"Northwestern University","biomarkers":" BRCA1 • BRCA2 • MSI • POLE • BAP1 • CDK12 • ERCC2 • CHEK2 • RAD51 • FANCA • POLD1 • RAD50 • CHEK1 • BARD1 • NBN • EMSY • FANCD2 • FANCE • PRKDC • FANCC","pipe":" | ","alterations":" MSI-H/dMMR • RAD50 mutation","tags":["BRCA1 • BRCA2 • MSI • POLE • BAP1 • CDK12 • ERCC2 • CHEK2 • RAD51 • FANCA • POLD1 • RAD50 • CHEK1 • BARD1 • NBN • EMSY • FANCD2 • FANCE • PRKDC • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • RAD50 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • veliparib (ABT-888)"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 05/23/2017","start_date":" 05/23/2017","primary_txt":" Primary completion: 03/11/2018","primary_completion_date":" 03/11/2018","study_txt":" Completion: 08/04/2020","study_completion_date":" 08/04/2020","last_update_posted":"2024-06-12"},{"id":"64f232bf-1136-4191-96e8-05f7092ed952","acronym":"COMPRENDO","url":"https://clinicaltrials.gov/study/NCT05033756","created_at":"2021-09-05T16:55:47.679Z","updated_at":"2025-02-25T16:16:39.031Z","phase":"Phase 2","brief_title":"Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO","source_id_and_acronym":"NCT05033756 - COMPRENDO","lead_sponsor":"Institut fuer Frauengesundheit","biomarkers":" HER-2 • PGR • BRCA1 • BRCA2 • ATM • HRD • CHEK2 • RAD51C • RAD51D • BARD1 • XRCC2 • FANCC • SLX4","pipe":" | ","alterations":" HER-2 amplification • HER-2 negative • HRD • ATM mutation • PALB2 mutation • CHEK2 mutation • PGR positive • RAD51C mutation • RAD51D mutation • BARD1 mutation","tags":["HER-2 • PGR • BRCA1 • BRCA2 • ATM • HRD • CHEK2 • RAD51C • RAD51D • BARD1 • XRCC2 • FANCC • SLX4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 negative • HRD • ATM mutation • PALB2 mutation • CHEK2 mutation • PGR positive • RAD51C mutation • RAD51D mutation • BARD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lynparza (olaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 11","initiation":"Initiation: 07/30/2022","start_date":" 07/30/2022","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-05-07"},{"id":"3fa56835-b064-485b-a887-6a32c8d18aac","acronym":"KNIGHTS","url":"https://clinicaltrials.gov/study/NCT06212583","created_at":"2024-01-19T15:18:40.511Z","updated_at":"2025-02-25T16:27:47.221Z","phase":"Phase 2","brief_title":"High-Risk Metachronous Oligometastatic Prostate Cancer Trial","source_id_and_acronym":"NCT06212583 - KNIGHTS","lead_sponsor":"University of Maryland, Baltimore","biomarkers":" TP53 • BRCA1 • CHEK2 • RAD51B • RAD54L","pipe":" | ","alterations":" ATM mutation • PALB2 mutation","tags":["TP53 • BRCA1 • CHEK2 • RAD51B • RAD54L"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • PALB2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • abiraterone acetate • prednisone"],"overall_status":"Recruiting","enrollment":" Enrollment 88","initiation":"Initiation: 04/17/2024","start_date":" 04/17/2024","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 12/31/2029","study_completion_date":" 12/31/2029","last_update_posted":"2024-04-23"},{"id":"f976983e-6e5c-40aa-ba00-71e22eb80e0e","acronym":"ATRIUM","url":"https://clinicaltrials.gov/study/NCT05338346","created_at":"2022-04-21T15:55:20.706Z","updated_at":"2024-07-02T16:35:08.451Z","phase":"Phase 1","brief_title":"A Study of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological Malignancies","source_id_and_acronym":"NCT05338346 - ATRIUM","lead_sponsor":"Antengene Discovery Limited","biomarkers":" BRCA1 • BRCA2 • ATM • ARID1A • MSH2 • CDK12 • ATRX • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC","pipe":" | ","alterations":" TP53 mutation • FANCF mutation","tags":["BRCA1 • BRCA2 • ATM • ARID1A • MSH2 • CDK12 • ATRX • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FANCF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATG-018"],"overall_status":"Recruiting","enrollment":" Enrollment 88","initiation":"Initiation: 07/08/2022","start_date":" 07/08/2022","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2024-04-22"},{"id":"04495210-d346-4ec0-a195-5cf3933896b6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05038839","created_at":"2021-09-09T13:53:06.097Z","updated_at":"2024-07-02T16:35:09.419Z","phase":"Phase 1","brief_title":"Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors","source_id_and_acronym":"NCT05038839","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRCA1 • BRCA2 • PTEN • ARID1A • CHEK2 • RAD50 • PARP1 • CHEK1 • EMSY","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation • CHEK2 mutation • RAD50 mutation • CHEK1 mutation • CHEK1 expression","tags":["BRCA1 • BRCA2 • PTEN • ARID1A • CHEK2 • RAD50 • PARP1 • CHEK1 • EMSY"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation • CHEK2 mutation • RAD50 mutation • CHEK1 mutation • CHEK1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet) • Partruvix (pamiparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 02/09/2022","start_date":" 02/09/2022","primary_txt":" Primary completion: 06/03/2024","primary_completion_date":" 06/03/2024","study_txt":" Completion: 06/03/2024","study_completion_date":" 06/03/2024","last_update_posted":"2024-04-16"},{"id":"ae2fbbdf-1d9d-47eb-9888-dad360517475","acronym":"MATRIX","url":"https://clinicaltrials.gov/study/NCT05986071","created_at":"2023-08-14T15:09:50.416Z","updated_at":"2025-02-25T16:19:00.084Z","phase":"Phase 1/2","brief_title":"I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers","source_id_and_acronym":"NCT05986071 - MATRIX","lead_sponsor":"Institut Paoli-Calmettes","biomarkers":" HER-2 • ER • BRCA1 • BRCA2 • ATM • RB1 • ARID1A • CDK12 • ATRX • BRCA • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • RAD54L • FANCL • PPP2R2A • ERCC4 • FANCD2 • XRCC1","pipe":" | ","alterations":" HR positive • HER-2 negative • ATM mutation • ARID1A mutation • PALB2 mutation","tags":["HER-2 • ER • BRCA1 • BRCA2 • ATM • RB1 • ARID1A • CDK12 • ATRX • BRCA • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • RAD54L • FANCL • PPP2R2A • ERCC4 • FANCD2 • XRCC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • ATM mutation • ARID1A mutation • PALB2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • tuvusertib (M1774)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 57","initiation":"Initiation: 05/01/2024","start_date":" 05/01/2024","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 10/15/2027","study_completion_date":" 10/15/2027","last_update_posted":"2024-03-29"}]